Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target Customer
Healthcare & Life SciencesHealthcareProvidersPatients
Core Technology
Materials & Substances
Tags (9)
doctorscatheterssurgeryvalveshospitalsmedical-devicescardiologyheart-diseasesminimally-invasive
Cardiovalve Financials
Undisclosed
Capital raised
Cumulative Funding Raised Over Time ($)
$40.0MAug 2020
$45.5MNov 2016
Private Equity Funding
Edwards Lifesciences, OXO Ventures, NGN Capital, Peregrine Ventures, Amir Gross, GlenRock Group
Cardiovalve Lifecycle
Cumulative Funding Raised Over Time
$40.0MAug 2020
$45.5MNov 2016
All Events
Edwards Lifesciences, OXO Ventures, NGN Capital, Peregrine Ventures, Amir Gross, GlenRock Group
Cardiovalve News
4 articles
Venus Medtech Completes Equity Interest Deal with Cardiovalve
Chinese company Venus Medtech has completed its acquisition of Israeli transcatheter mitral and tricuspid valve treatment firm Cardiovalve. The acquisition allows Venus Medtech to become a market leader in the Chinese mitral and tricuspid regurgitation treatment markets. Cardiovalves transfemoral approach and innovative valve design have earned FDA early feasibility study approval for both indications. The market value for mitral and tricuspid regurgitation interventional therapy is expected to reach $5 billion by 2028. The acquisition is seen as a significant step in Venus Medtechs international development strategy.
Acquisition
China's Venus Medtech buys Israeli co Cardiovalve
Israeli heart valve treatment company Cardiovalve has been acquired by Chinese company Venus Medtech for $150 million upfront and an additional $150 million dependent on reaching regulatory milestones. Venus Medtech has also committed to investing another $100 million in Cardiovalve. Cardiovalve was founded by CEO Amir Gross, who previously founded Valtech Cardio. Valtech Cardio was acquired by Edwards Lifesciences in 2017 for $340 million upfront and a potential total consideration of $1 billion. The investors of Valtech Cardio have received an estimated $500-600 million. Venus Medtech is a major player in the Chinese heart medical devices market and has a market cap of $1.6 billion. The acquisition is expected to contribute to the growth of Cardiovalve in the global market.
Acquisition
Cardiovalve simplifies heart valve replacement
Israeli company Cardiovalve, a spin-off of Valtech Cardio, is developing a device for minimally-invasive valve replacement. The companys product offers several benefits, including different sizes suitable for 95% of the population and a delivery system that saves on costs. Edwards Lifesciences, which acquired Valtech in 2017, did not acquire Cardiovalves next-generation product but has invested in the company. Cardiovalve has received about $40 million in investments, and the market for minimally invasive mitral valve replacement is estimated at $3-3.5 billion. The company aims to begin trials for marketing approval in Europe later this year and enter the market in about four years. Cardiovalve has also developed a product for the tricuspid valve.
InvestmentExpand
Cardiovalve Receives 'Breakthrough Device Designation' for Its Transcatheter Tricuspid Valve Replacement System
Employee Info
| Employees (range) | 51-200 |
| Exact count | 51 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
